Completion of allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in a Heart failure trial

Heart failure is a serious condition with a high morbidity and mortality. The patient enrolment and 1 year follow-up has been finalized for all heart failure patients in the Danish Ischemic Heart Failure phase II Trial (81 patients), in the International multi-centre SCIENCE Ischemic Heart Failure Phase II Trial (133 patients) and in the Non-Ischemic Heart Failure Phase I-II Trial (30 patients).

All safety and efficacy data will be ready for publication late 2021.